GE Healthcare Technologies
GE HEALTHCARE TECHNOLOGIES INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$20.6B
Operating marginCalculated
13.4%
Net assets to total assetsCalculated
28.1%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
13.4%
Growth (revenue, 4-year average)
★★★☆☆position among all companies
4.1%
Capital efficiency
★★★★☆position among all companies
20.1%
Revenue and profit
Performance, financial position and capital allocation
GE Healthcare Technologies
Recent performance trends
GE Healthcare Technologies
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$17.6 billion | US$18.3 billion | US$19.6 billion | US$19.7 billion | US$20.6 billion |
| Operating income | US$2.8 billion | US$2.5 billion | US$2.4 billion | US$2.6 billion | US$2.8 billion |
| Net income | US$2.2 billion | US$1.9 billion | US$1.6 billion | US$2.0 billion | US$2.1 billion |
| Total assets | Could not be retrieved | US$27.5 billion | US$32.5 billion | US$33.1 billion | US$36.9 billion |
| Shareholders' equity | Could not be retrieved | US$9.4 billion | US$7.1 billion | US$8.4 billion | US$10.4 billion |
| Net cash provided by (used in) operating activities | US$1.6 billion | US$2.1 billion | US$2.1 billion | US$2.0 billion | US$2.0 billion |
| Net cash provided by (used in) investing activities | US$-1.8 billion | US$-0.4 billion | US$-0.6 billion | US$-0.9 billion | US$-1.0 billion |
| Net cash provided by (used in) financing activities | US$-0.3 billion | US$-0.8 billion | US$-0.5 billion | US$-0.6 billion | US$0.6 billion |
| Cash and cash equivalents | Could not be retrieved | US$1.4 billion | US$2.5 billion | US$2.9 billion | US$4.5 billion |
Revenue scale in the same industry
GE Healthcare Technologies
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 4 companies
- 8 BECTON, Dickinson ANDFY Sep 2025 US$21.8B
- 9 L3HARRIS TechnologiesFY Jan 2025 US$21.3B
- 10 GE Healthcare TechnologiesThis companyFY Dec 2025 US$20.6B
- 11 Boston ScientificFY Dec 2025 US$20.1B
- 12 KLAFY Jun 2026 US$13.6B
- … 31 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$4.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.0 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.3 billion | Consolidated | Disclosed |
| Dividends paid | US$64.00 million | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$10.4 billion | Consolidated | Disclosed |
| Non-controlling interests | US$11.00 million | Consolidated | Disclosed |
| Net assets | US$10.4 billion | Consolidated | Disclosed |
| Net sales | US$20.6 billion | Consolidated | Disclosed |
| Operating income | US$2.8 billion | Consolidated | Disclosed |
| Net income | US$2.1 billion | Consolidated | Disclosed |
| Total assets | US$36.9 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.2 billion | Consolidated | Disclosed |
| Operating margin | 13.4% | Consolidated | Calculated |
| Net assets to total assets | 28.1% | Consolidated | Calculated |
| Net margin | 10.1% | Consolidated | Calculated |
| Return on equity | 20.1% | Consolidated | Calculated |